Overview
- Editors:
-
-
Marie-Luise Sautter-Bihl
-
Klinik für Strahlentherapie, Städt. Kliniken Karlsruhe, Karlsruhe, Germany
-
Heiner Bihl
-
Klinik für Nuklearmedizin, Katharinenhospital Stuttgart, Stuttgart, Germany
-
Michael Wannenmacher
-
Radiologische Klinik Abteilung für Klinische Radiologie, Heidelberg, Germany
Access this book
Other ways to access
About this book
Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology.
Similar content being viewed by others
Table of contents (13 papers)
-
-
-
- D. J. Buchsbaum, P. L. Roberson
Pages 9-18
-
- F. Buchegger, J.-P. Mach, S. Folli, B. Delaloye, A. Bischof-Delaloye, A. Pèlegrin
Pages 19-35
-
-
- M.-L. Sautter-Bihl, G. Herbold, H. Bihl
Pages 67-75
-
-
- M. R. Zalutsky, J. M. Schuster, P. K. Garg, G. E. Archer Jr., M. W. Dewhirst, D. D. Bigner
Pages 101-122
-
- M. L. Sautter-Bihl, H. Bihl
Pages 123-135
-
-
- J. T. Kemshead, K. I. Hopkins, C. L. Chandler
Pages 145-158
-
- K. Hopkins, V. Papanastassiou, J. T. Kemshead
Pages 159-175
-
-
- C. T. Miyamoto, L. W. Brady, M. A. Rackover, J. Emrich, R. Class, H. Bender et al.
Pages 183-192
-
Back Matter
Pages 193-197
Reviews
"a timely and deliberately provocative new impetus to this long overdue discussion of promising, selective cancer treatment." Jnl. of the National Cancer Institute
Editors and Affiliations
-
Klinik für Strahlentherapie, Städt. Kliniken Karlsruhe, Karlsruhe, Germany
Marie-Luise Sautter-Bihl
-
Klinik für Nuklearmedizin, Katharinenhospital Stuttgart, Stuttgart, Germany
Heiner Bihl
-
Radiologische Klinik Abteilung für Klinische Radiologie, Heidelberg, Germany
Michael Wannenmacher